Dilated Cardiomyopathy clinical trials

Explore recruiting dilated cardiomyopathy clinical trials.

Recruiting dilated cardiomyopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dilated Cardiomyopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Clinical trial phase IIb multicenter, double-blind, randomized, placebo-controlled trial evaluating the efficacy of intracoronary infusion of autologous adult mononuclear bone marrow unexpanded on functional recovery in patients with dilated cardiomyopathy of idiopathic origin and heart failure.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).

Spain, Denmark, Belgium, Hungary, Italy, Poland +3 more

Phase II and Phase III (Integrated) EU CTIS Study details

Deciphering IL-1 mediated inflammation for the targeted treatment of dilated cardiomyopathy.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Treatment with Risedronate for dilated cardiomyopathy due to Troponin T alteration due to K210 deletion.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A trial to learn how safe AZD4063 is, how it moves throughout the body over time, and how it affects the levels of PLN mRNA in adults with dilated cardiomyopathy because of an R14del mutation in the PLN gene

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2, Open-Label, Dose Finding Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants with Symptomatic BAG3 Mutation-Associated Dilated Cardiomyopathy

Spain, Italy, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Dilated Cardiomyopathy trials by city

Dilated Cardiomyopathy in Toronto Dilated Cardiomyopathy in Vancouver Dilated Cardiomyopathy in Montreal Dilated Cardiomyopathy in Calgary Dilated Cardiomyopathy in Edmonton Dilated Cardiomyopathy in Ottawa Dilated Cardiomyopathy in Winnipeg Dilated Cardiomyopathy in Quebec City Dilated Cardiomyopathy in Hamilton Dilated Cardiomyopathy in Kitchener Dilated Cardiomyopathy in London Dilated Cardiomyopathy in Halifax Dilated Cardiomyopathy in New York Dilated Cardiomyopathy in Los Angeles Dilated Cardiomyopathy in Chicago Dilated Cardiomyopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease